Inhibrx, Inc.: Revision history

20 August 2022

• curprev 03:4103:41, 20 August 2022 95.149.241.133 talk 940 bytes +11 No edit summary undo

13 August 2022

• curprev 03:4403:44, 13 August 2022 109.180.50.163 talk 929 bytes +15 No edit summary undo

29 July 2022

• curprev 17:1317:13, 29 July 2022 >Chris 914 bytes +914 Created page with "Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Pha..."